Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.
about
Bronchoscopy-guided antimicrobial therapy for cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisNewborn screening for cystic fibrosisBacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current statusTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisThe Evolution of Cystic Fibrosis CareBacterial evolution in PCD and CF patients follows the same mutational stepsStructural and Functional Characterization of Pseudomonas aeruginosa AlgX: ROLE OF AlgX IN ALGINATE ACETYLATIONA conformational landscape for alginate secretion across the outer membrane ofPseudomonas aeruginosaInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.Airway Gland Structure and FunctionSynthase-dependent exopolysaccharide secretion in Gram-negative bacteria.Background and EpidemiologyRisk factors for lung function decline in a large cohort of young cystic fibrosis patients.Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosisNonparametric estimation of the mean function for recurrent event data with missing event category.Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severityProteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.Impact of multidrug-resistant organisms on patients considered for lung transplantation.Pulmonary outcome differences in U.S. and French cystic fibrosis cohorts diagnosed through newborn screening.The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyInfluenza-associated cystic fibrosis pulmonary exacerbations.The Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes.Rate of improvement of CF life expectancy exceeds that of general population--observational death registration study.Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentUse of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis.Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosisPseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypesPseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study.The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infectionPseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenaseActivation of the Pseudomonas aeruginosa AlgU regulon through mucA mutation inhibits cyclic AMP/Vfr signaling.Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.
P2860
Q24186413-1B46F97C-0E19-458B-BD96-7AB773531106Q24201620-3DFD21E9-1F82-4B88-A215-2817810249B8Q24234964-F834CB73-D546-4FB3-B305-AB5C2E1A6E3DQ24241094-FDD01D1F-E5CA-4283-BD83-66FE0A91458CQ26799417-337AF698-7B76-48D5-AA50-C9EF18FC4940Q26829604-8305EE26-5F67-4E86-A99B-29A63F3ADA7EQ26999299-3301DE8E-3478-4E38-8361-01F81431F9CEQ27334684-3DF35387-54FE-4FC7-872C-C2A674169F70Q27678695-06C8E2BB-CC4A-4755-A31D-8A365334940EQ27684899-A9560A18-A481-4056-B882-3E94783C4325Q28077482-B2F432E5-7D41-4B81-BC9A-9A20905B467EQ28082284-D21C42E6-CB4B-4246-930E-3826EDE7A1F9Q30155195-07CEC994-4180-4900-8C91-FE2204A2C1F0Q30248742-54485834-C041-47B6-83B6-929D5D6E9416Q30352400-C5F4976A-AF47-4999-ADAC-DD2F0F7C03C3Q30413773-A937A294-DCAE-4375-968B-D296DC687184Q30452653-7546A465-366C-4135-8B9B-FEBEFD848B09Q30731623-24F00FF0-29CB-4DCA-88FD-AF3CCBC737D4Q33402923-34F89603-ED46-411E-8AA0-6B4496FB57FAQ33474273-F043AC9A-EE7C-40AC-A4ED-3E2278899B8EQ33523793-8B8622CA-EE53-4372-AA65-AB6461686BCBQ33576059-A0058275-4C3A-4100-A62F-71BED76F56CFQ33637688-92FDBC1C-B41F-46E4-AF1C-044192EC2BC1Q33644835-3208D3D0-2A12-4D9B-ADF5-A1B06B493F39Q33688123-F0E63036-E63F-49E2-8C3F-24F1A1EDFB76Q33697276-34E27110-DBE6-4519-BD1A-E9C2C4D52627Q33776832-B784DD38-DEE3-4D7D-8786-03EC766CA064Q33780971-1D5E9689-C092-4AE8-8DBD-D7B65068E5EFQ33818393-ABA723C8-F91A-4279-9F2E-08F1985AA55EQ33824149-29AD079F-1683-4756-9A6F-DA39A35201D0Q33869527-61E2F178-87E8-4CB7-9969-9803D506BBC1Q34041909-8615DF87-B9FB-4A39-A669-F6AA368F2AF5Q34067203-6C345F0C-2A4E-4C06-8370-C73B3B0709A4Q34076289-9F035426-41D8-480E-9A11-F0F18E590633Q34085781-E3A815CA-E776-42EF-9E77-5FD3F799D4BFQ34105561-9BD6B32C-5C2A-4115-8983-3B96C4EF0D79Q34106186-5CCFE1C9-CC9B-44B2-8727-ECE8F9C9D5DBQ34124322-F3278BA9-6FC0-49FE-A112-A4101ACFB52DQ34192652-355FA113-64A7-4E46-A37E-66DC4A43E5EBQ34232085-95125F89-7901-4651-A82E-709E2DA20283
P2860
Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Longitudinal development of mu ...... children with cystic fibrosis.
@en
Longitudinal development of mu ...... children with cystic fibrosis.
@nl
type
label
Longitudinal development of mu ...... children with cystic fibrosis.
@en
Longitudinal development of mu ...... children with cystic fibrosis.
@nl
prefLabel
Longitudinal development of mu ...... children with cystic fibrosis.
@en
Longitudinal development of mu ...... children with cystic fibrosis.
@nl
P2093
P356
P1476
Longitudinal development of mu ...... children with cystic fibrosis
@en
P2093
Anita Laxova
Christopher G Green
Jannette Collins
Michael J Rock
Michael R Kosorok
Philip M Farrell
Susan E H West
Zhanhai Li
P304
P356
10.1001/JAMA.293.5.581
P407
P577
2005-02-01T00:00:00Z